



Global Health L i m i t e d

May 14, 2026

Ref:- GH/2026-27/EXCH/10

The General Manager
Dept. of Corporate Services
BSE Limited,
P J Towers, Dalal Street,
Mumbai - 400 001

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

Scrip Code: 543654

Symbol: MEDANTA

Sub: Press Release

Dear Sir(s),

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copy of the Press Release, for the fourth quarter and financial year ended March 31, 2026 Results.

Kindly take the above on record.


Thanking you,

Yours faithfully

For Global Health Limited

Rahul Ranjan
Company Secretary & Compliance Officer
M. No. A17035

Encl: a/a



Medanta delivered highest ever quarterly Revenue of INR 11,958 million and EBITDA INR 2,906 million in Q4 FY26

Consolidated Total Income INR 45,089 million, up by 19.6% y-o-y in FY26

EBITDA ex Noida of INR 11,343 million, up by 18.6% y-o-y with margins of 25.7% in FY26

Gurugram, 14th May, 2026: Global Health Limited (NSE: [Medanta](#), BSE: [543654](#)), one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, today announced its audited consolidated financial results for the quarter and full year ending 31st March, 2026.

Consolidated Highlights of the Year Ended 31st March, 2026 (FY2026)

- Consolidated Total Income of INR 45,089 million, strong growth of 19.6% y-o-y
- EBITDA (ex-Noida) grew by 18.6% y-o-y to INR 11,343 with margins of 25.7%. EBITDA Including Noida was INR 10,560 million, with margins at 24.2%
- Medanta Noida, formally inaugurated in November 2025, is now fully operational with 382 beds, including 98 ICU beds and 14 operating theatres. In FY2026, the hospital reported revenue of INR 906 million and an EBITDA loss of INR 783 million. The facility is steadily gaining momentum, with quarterly start-up losses showing a declining trend
- Profit After Tax was INR 5,541 million, growth of 15.1% y-o-y
- The Board of Directors have recommended a final dividend of 25% on the face value of INR 2 per share i.e. INR 0.50 per share
- Total beds grew by 20.5% y-o-y, with 623 bed addition in FY26. The bed increase comprises of 382 beds at Noida, 131 beds at Patna, and commissioning of a new 110-bed hospital in Ranchi
- Volume growth remained robust, In-patient count increased by 16.0% and Out-patient count increased by 18.7% y-o-y
- Average occupied bed days increased by 11.3% y-o-y, representing an occupancy of ~62% on increased bed capacity
- ARPOB grew by 6.1% y-o-y to INR 66,550, driven by improvement in ALOS and change in case mix
- Matured hospitals revenue was INR 28,482 million, growth of 9.0% y-o-y. EBITDA was INR 6,946 million, growth of 7.2% y-o-y
- Developing hospitals ex Noida, reported revenue of INR 14,130 million, growth of 29.2% y-o-y. EBITDA increased by 35.2% y-o-y to INR 4,447 million, with margins improving to 31.5% compared to 30.1% in FY25
- International Patients Revenue increased by 33.2% y-o-y to INR 2,780 million
- OPD Pharmacy (Hospital & Retail) continues to register strong double digit growth. Revenue increased by 30.4% y-o-y to INR 1,826 million in FY26

Consolidated Highlights of the Quarter Ended 31st March, 2026 (Q4 FY2026)

- Highest ever quarterly total income of INR 11,958 million; growth of 25.3% y-o-y
- EBITDA (ex-Noida) grew 27.0 % y-o-y to INR 3,142 with improved margins of 27.5% in Q4 FY26. EBITDA including Noida was INR 2,906 million, growth of 17.4% y-o-y and margins of 24.3%
- Noida hospital generated Total Income of INR 525 million in Q4 FY26 and EBITDA loss of INR 236 million in Q4 FY26, compared to loss of INR 320 million reported in Q3 FY26
- Profit After Tax was INR 1,417 million, robust growth of 39.7% y-o-y. PAT margins improved to 11.8% from 10.6% in Q4 FY25
- During the quarter, total 86 new bed added, 32 in added at Patna and 54 beds in Noida
- Volume growth remained robust, In-patient count increased by 23.0% and Out-patient count increased by 27.5% y-o-y
- Occupied bed days increased by 18.0% y-o-y, representing an occupancy of ~61% on increased bed capacity and occupancy of ~64% excluding Noida hospital
- ARPOB was INR 66,687, up by 4.8% y-o-y, driven by improvement in ALOS and change in case mix
- During the quarter, International Patients Revenue increased by 22.0% y-o-y to INR 679 million, marginally down on a sequential basis due to flight disruptions
- OPD Pharmacy (Hospital & Retail) business continues to register strong growth. Revenue increased by 46.2% y-o-y to INR 496 million in Q4 FY26

Commenting on FY2026 results, Mr. Pankaj Sahni, Group CEO and Director said:

“FY2026 marked another year of strong execution for Medanta, with robust operational and financial performance across the network. Growth was driven by higher patient volumes, improved realizations, and consistent delivery across our hospitals.

During the year, we successfully operationalized our 550-bed Noida hospital, which achieved NABH accreditation within the first six months, underscoring the strength of our institutional systems and clinical protocols. The facility is now fully operational, supported by 200+ clinicians, 382 beds, 14 operating theatres, and advanced medical technologies. The ramp-up is progressing well and is increasingly reflected in our financial performance.

Reinforcing our commitment to quality, our Lucknow hospital received JCI accreditation, becoming the first hospital in Uttar Pradesh to earn this distinction. Medanta Gurugram was also recognized by Newsweek as India’s Best Hospital and for the seventh consecutive year is ranked among the world’s top 150 hospitals.

Medanta expanded its bed capacity by 20% during the year. We expect to add ~500 beds across existing hospitals over the next 12 months and ~2,700 beds through five greenfield projects over the next 3–4 years. Backed by a strong balance sheet and deep clinical expertise, we remain focused on strengthening our network through a disciplined and calibrated approach to expansion, anchored in quality.”

Key Developments - FY2026

- Group: Total 623 beds added during the year, 20.5% bed growth
- Noida: Noida hospital inaugurated in September 26, 382 beds, 14 OTs operationalized at the end of FY2026
- Patna: Total 131 beds including 119 census beds and 12 day care beds added
- Ranchi New Unit: 110 bedded newly constructed hospital in close proximity to existing Ranchi hospital operationalized in June 25
- Guwahati, Assam: Board has approved project to build a 400 bedded hospital in Guwahati. Land purchase completed in September 25
- Varanasi, Uttar Pradesh: 400-bed hospital project approved by board in March 2026 under a built to suit and lease arrangement with partner
- Indore Cancer Unit: Addition of an ~80-bed cancer hospital under a business transfer agreement, announced in April 2026, to be operationalized in Q2 FY27
- On-boarded 550+ doctors including 200+ senior clinicians across the Medanta network to further strengthen clinical capabilities and patient care deliver

Financial Highlights: Q4 and FY26

INR million	Year End			Quarter			
	FY2026	FY2025	Y-o-Y Growth %	Q4 FY26	Q3 FY26	Q4 FY25	Y-o-Y Growth %
Revenue from operations	44,103	36,923	19.4%	11,590	11,211	9,313	24.5%
Other income	986	789	24.9%	367	217	229	60.3%
Total income	45,089	37,713	19.6%	11,958	11,428	9,542	25.3%
Cost of materials consumed	9,968	8,797	13.3%	2,465	2,557	2,136	15.4%
Employee benefits expense	17,158	13,219	29.8%	4,615	4,498	3,356	37.5%
Other expenses	7,403	6,136	20.7%	1,971	1,880	1,573	25.3%
EBITDA	10,560	9,562	10.4%	2,906	2,494	2,476	17.4%
EBITDA Margins %	23.4%	25.4%	(193) bps	24.3%	21.8%	26.0%	(165) bps
ESOP Expenses	383	0	na	101	103	0	na
EBITDA after ESOP Expenses	10,177	9,562	6.4%	2,805	2,391	2,476	13.3%
Finance costs	791	653	21.2%	267	215	150	77.7%
Depreciation and amortisation expense	2,225	1,937	14.9%	665	612	493	35.1%
Exceptional item expense ¹ (income)	10	499	(98.0)%	0	366	499	(100.0)%
Profit before tax	7,150	6,473	10.5%	1,873	1,198	1,334	40.3%
Tax expenses	1,609	1,659	(3.0)%	456	248	321	42.3%
Profit after tax	5,541	4,813	15.1%	1,417	950	1,014	39.7%

About Global Health Limited (Medanta)

Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third- and fourth-highest civilian awards in India, and the Dr. B.C. Roy Award in recognition of his distinguished contribution to medicine.

Global Health Limited (the “Company”) is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology, according to the report titled “An assessment of the healthcare delivery market in India, September 2022” by CRISIL Limited.

Under the “Medanta” brand, the Company has a network of six hospitals currently in operation (Gurgaon, Indore, Ranchi, Lucknow, Patna and Noida). Spanning an area of 5.6 million sq. ft., its operational hospitals have 3,633 installed beds as on March 31, 2026. It also has five upcoming hospitals in Mumbai, Delhi (Pitampura, New Delhi, South Delhi), Guwahati and Varanasi. The Company provides healthcare services in over 30 medical specialties and engages over 2,400+ doctors led by highly experienced department heads.

For more information visit www.medanta.org or contact:

Global Health Limited**Ravi Gothwal**ravi.gothwal@medanta.org

Tel: 0124 – 4141 414

Bhushan Khandelwalbhushan.khandelwal@medanta.org

Tel: 0124 – 4141 414

Safe Harbour Disclaimer

This press release, apart from historical information, contains some “forward-looking statements” including those describing the Company’s strategies, strategic direction, objectives, future prospects, estimates etc. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by these statements. These factors include, but are not limited to general market conditions, macro-economic, movements in currency exchange and interest rates, the ability to attract and retain high quality human resource, competitive pressures, technological developments, governmental and regulatory trends, legislative developments, and other key factors beyond the control of the Company.

These forward looking statements are based on information currently available to us, and we assume no obligation to revise these statements as circumstances change. The Company may alter, modify or otherwise change in any manner the content of Presentation/Press Release, without obligation to notify any person of such revision or changes.